image
Healthcare - Medical - Healthcare Plans - NYSE - US
$ 63.85
0.298 %
$ 80.5 B
Market Cap
17.45
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CVS stock under the worst case scenario is HIDDEN Compared to the current market price of 63.9 USD, CVS Health Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CVS stock under the base case scenario is HIDDEN Compared to the current market price of 63.9 USD, CVS Health Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CVS stock under the best case scenario is HIDDEN Compared to the current market price of 63.9 USD, CVS Health Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CVS

image
$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
373 B REVENUE
4.20%
8.52 B OPERATING INCOME
-38.03%
4.59 B NET INCOME
-45.20%
9.11 B OPERATING CASH FLOW
-32.17%
-7.61 B INVESTING CASH FLOW
63.55%
-1.14 B FINANCING CASH FLOW
-42.30%
97.7 B REVENUE
2.39%
2.37 B OPERATING INCOME
184.62%
1.62 B NET INCOME
2185.92%
1.86 B OPERATING CASH FLOW
349.66%
-547 M INVESTING CASH FLOW
83.66%
431 M FINANCING CASH FLOW
127.14%
Balance Sheet CVS Health Corporation
image
Current Assets 68.6 B
Cash & Short-Term Investments 11 B
Receivables 36.5 B
Other Current Assets 21.2 B
Non-Current Assets 185 B
Long-Term Investments 28.9 B
PP&E 28.9 B
Other Non-Current Assets 127 B
4.34 %14.40 %8.37 %11.43 %11.43 %50.04 %Total Assets$253.2b
Current Liabilities 84.6 B
Accounts Payable 15.9 B
Short-Term Debt 7.49 B
Other Current Liabilities 61.2 B
Non-Current Liabilities 92.9 B
Long-Term Debt 75.4 B
Other Non-Current Liabilities 17.4 B
8.95 %4.22 %34.49 %42.50 %9.83 %Total Liabilities$177.5b
EFFICIENCY
Earnings Waterfall CVS Health Corporation
image
Revenue 373 B
Cost Of Revenue 321 B
Gross Profit 51.4 B
Operating Expenses 41.6 B
Operating Income 8.52 B
Other Expenses 3.93 B
Net Income 4.59 B
400b400b350b350b300b300b250b250b200b200b150b150b100b100b50b50b00373b(321b)51b(42b)9b(4b)5bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
13.79% GROSS MARGIN
13.79%
2.28% OPERATING MARGIN
2.28%
1.24% NET MARGIN
1.24%
6.11% ROE
6.11%
1.82% ROA
1.82%
3.61% ROIC
3.61%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CVS Health Corporation
image
16b16b14b14b12b12b10b10b8b8b6b6b4b4b2b2b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 4.59 B
Depreciation & Amortization 4.6 B
Capital Expenditures -2.78 B
Stock-Based Compensation 0
Change in Working Capital 109 M
Others 198 B
Free Cash Flow 6.33 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CVS Health Corporation
image
Wall Street analysts predict an average 1-year price target for CVS of $71.8 , with forecasts ranging from a low of $63 to a high of $86 .
CVS Lowest Price Target Wall Street Target
63 USD -1.33%
CVS Average Price Target Wall Street Target
71.8 USD 12.37%
CVS Highest Price Target Wall Street Target
86 USD 34.69%
Price
Max Price Target
Min Price Target
Average Price Target
90908585808075757070656560605555505045454040May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
1.48% DIVIDEND YIELD
0.665 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
3.0003.0002.5002.5002.0002.0001.5001.5001.0001.0000.5000.5000.0000.0000.350.4250.50.50.50.50.50.550.6050.6650.6650.350.4250.50.50.50.50.50.550.6050.6650.6650.350.4250.50.50.50.50.50.550.6050.6650.351.400.4251.700.52.000.52.000.52.000.52.000.52.000.552.200.6052.420.6652.661.332015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership CVS Health Corporation
image
Sold
0-3 MONTHS
498 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
2 M USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
554 K USD 2
9-12 MONTHS
7. News
CVS Health's Trough Years Are Here - Double Digits Return Profile Ahead CVS has been worst hit by the rising healthcare utilization/ medical costs, as observed in the relatively higher medical benefit ratio in FQ4'24/ FY2024 compared to its peers. Even so, we believe that FY2024 (and maybe FY2025) are likely to be its trough years, as the management offers promising guidance and the consensus raises forward estimates. Despite industry-wide issues, CVS remains well positioned to weather through the near-term uncertainties, thanks to the pricing increases and the stable balance sheet health. seekingalpha.com - 2 weeks ago
CVS Health: Undervalued, But The Road To Success Is Paved With Uncertainty I rate CVS Health as a BUY due to its undervaluation and potential for financial growth despite current sector uncertainties. CVS's revenue is growing, but profitability is declining due to retail competition and PBMs shrinking reimbursement rates. CVS's PBM business, Caremark, holds a significant market share, positioning it better than competitors like Walgreens. seekingalpha.com - 2 weeks ago
Why CVS Health (CVS) is Poised to Beat Earnings Estimates Again CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com - 2 weeks ago
Live Update: High-Yield Dividends Stocks React to China's Tariff Retaliation The stock market remains in freefall, today on fears of a full-blown trade war having been ignited, sending the stock market officially into correction turf. 247wallst.com - 2 weeks ago
Best performing S&P 500 stocks of Q1 2025 As the first quarter of 2025 wrapped up, the initial wave of optimism that carried markets into the new year had largely faded. Stocks opened strong, fueled by momentum from the late 2024 post-election rally, but the broader market lost ground as trade war fears and economic uncertainty weighed heavily on sentiment. finbold.com - 2 weeks ago
CVS Health to hold first quarter 2025 earnings conference call WOONSOCKET, R.I. , April 3, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Thursday, May 1 st, 2025, at 8:00 a.m. prnewswire.com - 2 weeks ago
CVS Health (CVS) Rises Yet Lags Behind Market: Some Facts Worth Knowing In the most recent trading session, CVS Health (CVS) closed at $68.07, indicating a +0.13% shift from the previous trading day. zacks.com - 2 weeks ago
Biotech Stocks Q1 2025 Recap: Winners And Underperformers Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone. seekingalpha.com - 2 weeks ago
CVS Health and Deckers Are the S&P 500's Best and Worst for the Quarter. Here's Why. CVS Health gained 50% over the three-month period while Deckers fell nearly as much. barrons.com - 2 weeks ago
The 3 Best Performing S&P 500 Stocks of 2025 Q1 We're nearing the end of the calendar-year Q1, with many S&P 500 stocks delivering strong performances year-to-date despite recent volatility stemming from tariff talks and other economic developments. zacks.com - 2 weeks ago
Stocks: Best and worst performers of Q1 On the final day of the first quarter of 2025, Madison Mills and Julie Hyman take a look at the best and worst-performing stocks and sectors of the year so far. Among the worst performers are Deckers (DECK) and Tesla (TSLA), while CVS Health (CVS) led gains. youtube.com - 2 weeks ago
CVS Health: I Don't Understand The Fuss, But The Worst Is Behind CVS Health experienced a significant turnaround in 2025, with shares up nearly 50% after a 44% decline in 2024. The recent rally is not driven by great results or strong guidance under new CEO leadership, but rather bad ones that just weren't as terrible as expected. CVS's 2025 outlook includes modest revenue growth, improved operating income, and a focus on stabilizing margins and profitability. seekingalpha.com - 3 weeks ago
8. Profile Summary

CVS Health Corporation CVS

image
COUNTRY US
INDUSTRY Medical - Healthcare Plans
MARKET CAP $ 80.5 B
Dividend Yield 1.48%
Description CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company's Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. As of December 31, 2021, it operated approximately 9,900 retail locations and 1,200 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Contact One CVS Drive, Woonsocket, RI, 02895 https://www.cvshealth.com
IPO Date Nov. 20, 1996
Employees 219000
Officers Mr. Prem S. Shah Pharm.D Executive Vice President & Group President Mr. Samrat S. Khichi Esq. Executive Vice President, Chief Policy Officer & General Counsel Mr. Tilak Mandadi Executive Vice President of Ventures and Chief Digital, Data, Analytics & Technology Officer Mr. Vijay Patel Senior Director of Business Development & CVS Health and Partner & Co-Founder Mr. Thomas Francis Cowhey Executive Vice President & Chief Financial Officer Mr. David A. Falkowski Executive Vice President & Chief Compliance Officer Mr. J. David Joyner CEBS President, Chief Executive Officer & Director Mr. James David Clark Senior Vice President, Controller & Chief Accounting Officer Ms. Heidi B. Capozzi Executive Vice President & Chief People Officer Mr. Roger N. Farah Executive Chairman of the Board